Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Truth in a cell

Single cell partnership for Fluidigm, Wellcome and EBI; Allergy center in Stanford; Takeda joins Monash for GI discovery

Fluidigm Corp., Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI) have teamed up to develop single cell analyses able to find information that is normally hidden in the noise of bulk cell populations.

Robert Jones, EVP of R&D at Fluidigm, told BioCentury, "The ability to analyze RNA, DNA and protein from single cells will allow researchers to see things that they would not otherwise see. If you look at the bulk average of a population of cells it is a lie and you just get the wrong answer."

The deal, announced in mid-December, formalizes an existing collaboration between Fluidigm and the founders of the Single Cell Genomics Centre (SCGC) on the Wellcome Trust Genome Campus. The informal phase of the partnership started in 2013

Read the full 1240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers